The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Launched by ERASMUS MEDICAL CENTER · Feb 20, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The RECMAP study is looking into the best ways to perform surgery for patients with recurrent glioblastoma, a type of aggressive brain tumor. Researchers want to compare two methods of mapping brain function during surgery—one where patients are awake and one where they are asleep—against surgeries without any mapping techniques. The goal is to see which method helps patients recover better, minimizes the amount of tumor left after surgery, and ultimately improves their quality of life.
To be eligible for this study, participants must be between 18 and 90 years old and have a diagnosed recurrent glioblastoma that is located in areas of the brain responsible for important functions, such as movement or speech. Patients will be closely monitored for up to six months after their surgery to assess their recovery and any potential complications. The study is being conducted across multiple centers in Europe and North America, and it aims to enroll patients over the next four years.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years and ≤90 years
- • 2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma
- • 3. Tumors situated in or near eloquent areas; motor cortex, sensory cortex, subcortical pyramidal tract, speech areas or visual areas as indicated on MRI (Sawaya Grading II and II)19
- • 4. The tumor is suitable for resection (according to neurosurgeon)
- • 5. Written informed consent
- Exclusion Criteria:
- • 1. Tumors of the cerebellum, brainstem, or midline
- • 2. Multifocal contrast-enhancing lesions
- • 3. Medical reasons precluding MRI (e.g., pacemaker)
- • 4. Inability to give written informed consent
- • 5. Secondary high-grade glioma due to malignant transformation from low-grade glioma
- • 6. Clinical data unavailable for the newly diagnosed setting
About Erasmus Medical Center
Erasmus Medical Center, located in Rotterdam, Netherlands, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution within the Erasmus University Rotterdam, the center integrates cutting-edge scientific inquiry with comprehensive patient care, focusing on a wide range of medical specialties. With a strong emphasis on multidisciplinary collaboration, Erasmus Medical Center aims to translate research findings into tangible clinical applications, enhancing treatment options and improving patient outcomes. The institution is dedicated to conducting ethical and rigorous clinical trials that contribute to the global body of medical knowledge and foster advancements in personalized medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
San Francisco, California, United States
Heidelberg, , Germany
Leuven, , Belgium
Munich, , Germany
The Hague, , Netherlands
Rotterdam, Zuid Holland, Netherlands
Bern, , Switzerland
Patients applied
Trial Officials
Jasper Gerritsen, MD PhD
Principal Investigator
Erasmus Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported